Datasheet

CALHM1 Antibody
CATALOG NUMBER: 5593

Availability: In stock

$0.00
Product Price Options

* Required Fields

$0.00
Specifications
Properties
Additional Info
Background

Specifications

SPECIES REACTIVITY:Human, Mouse, Rat
TESTED APPLICATIONS:ELISA, IF, IHC-P, WB
APPLICATIONS:CALHM1 antibody can be used for detection of CALHM1 by Western blot at 1 - 2 μg/mL. Antibody can also be used for immunohistochemistry starting at 5 μg/mL. For immunofluorescence start at 20 μg/mL.
USER NOTE:Optimal dilutions for each application to be determined by the researcher.
POSITIVE CONTROL:1) Cat. No. 1464 - Rat Liver Tissue Lysate
IMMUNOGEN:CALHM1 antibody was raised against a 17 amino acid synthetic peptide near the amino terminus of human CALHM1.

The immunogen is located within amino acids 60 - 110 of CALHM1.
HOST SPECIES:Rabbit

Properties

PURIFICATION:CALHM1 Antibody is affinity chromatography purified via peptide column.
PHYSICAL STATE:Liquid
BUFFER:CALHM1 Antibody is supplied in PBS containing 0.02% sodium azide.
CONCENTRATION:1 mg/mL
STORAGE CONDITIONS:CALHM1 antibody can be stored at 4˚C for three months and -20˚C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
CLONALITY:Polyclonal
ISOTYPE:IgG
CONJUGATE:Unconjugated

Additional Info

ALTERNATE NAMES:CALHM1 Antibody: FAM26C, FAM26C, Calcium homeostasis modulator protein 1, Protein FAM26C
ACCESSION NO.:NP_001001412
PROTEIN GI NO.:194440685
OFFICIAL SYMBOL:CALHM1
GENE ID:255022

Background

BACKGROUND:CALHM1 Antibody: Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by a massive loss of neurons in several brain regions and by the presence of senile plaques comprised of aggregated amyloid-beta (Abeta) peptides produced by the endoproteolysis of the amyloid precursor protein (APP). The calcium homeostasis modulator 1 (CALHM1) is a recently identified multipass transmembrane glycoprotein that controls cytosolic Ca2+ concentration and Abeta levels. While some studies suggest CALHM1 is significantly associated with risk of AD, other reports suggest there is no link. CALHM1 has been suggested to modulate the Ca2+-dependent proteolytic process of APP through controlling the level of cytosolic Ca2+.
REFERENCES: 1) Mattson MP. Pathways towards and away from Alzheimer’s disease. Nature2004; 430:631-9.
2) Dreses-Werringloer U, Lambert JC, Vingtdeux V, et al. A polymorphism in CALHM1 influences Ca2+ homeostasis, Ab levels, and Alzheimer ’s disease risk. Cell2008; 133:1149-61.
3) Nacmias B, Tedde A, Bagnoli S, et al. Lack of implication for CALHM1 P86L common variation in Italian patients with early and late onset Alzheimer ’s disease. J. Alzheimers Dis.2010; epub.

For Research Use Only